Latest Breaking News On - சீன சமூகம் - Page 7 : comparemela.com

SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China. The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. A total of 514 patients were enrolled. The co-primary endpoints were progression-free survival (PFS) as assessed by the Blinded I

United statesSan franciscoRuihua xuPatricia keeganJunshi biosciencesZhi liEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer centerNational reimbursement drug listNational medical products administrationPr teamNew drug application